Reducing the Risk of Distant Metastases: A Better End Point in Adjuvant Aromatase Inhibitor Breast Cancer Trials?

By Tang Shou-Ching  

Cancer Investigation, Vol. 26, Iss. 5, 2008-06 ,pp. : 481-490

Informa Healthcare

Access to resources Recommend Favorite

Prognostic impact of progesterone receptor status combined with body mass index in breast cancer patients treated with adjuvant aromatase inhibitor

By              

Oncology Letters, Vol. 10, Iss. 5, 2015-01 ,pp. : 3286-3292

Spandidos Publications

Access to resources Recommend Favorite

Aromatase inhibitor therapy and hair loss among breast cancer survivors

By Gallicchio Lisa   Calhoun Carla   Helzlsouer Kathy  

Breast Cancer Research and Treatment, Vol. 142, Iss. 2, 2013-11 ,pp. : 435-443

Springer Publishing Company

Access to resources Recommend Favorite

A Randomised Trial Comparing Two Doses of the New Selective Aromatase Inhibitor Anastrozole (Arimidex) With Megestrol Acetate in Postmenopausal Patients With Advanced Breast Cancer

By Berry J.   Sahlberg P.   ARIMIDEX Study Group   Jonat W.   Howell A.   Blomqvist C.   Eiermann W.   Winblad G.   Tyrrell C.   Mauriac L.   Roche H.   Lundgren S.   Hellmund R.   Azab M.  

European Journal of Cancer, Vol. 32, Iss. 3, 1996-03 ,pp. : 404-412

Elsevier

Access to resources Recommend Favorite

Vitamin D threshold to prevent aromatase inhibitor-related bone loss: the B-ABLE prospective cohort study

By Prieto-Alhambra Daniel   Servitja Sonia   Javaid M.   Garrigós Laia   Arden Nigel   Cooper Cyrus   Albanell Joan   Tusquets Ignasi   Diez-Perez Adolfo   Nogues Xavier  

Breast Cancer Research and Treatment, Vol. 133, Iss. 3, 2012-06 ,pp. : 1159-1167

Springer Publishing Company

Access to resources Recommend Favorite